Chinese neurotechnology company BrainCo, a rival to Elon Musk's Neuralink, is developing a non-invasive wearable device designed to suppress appetite through brain stimulation, potentially challenging conventional obesity treatments.
The Hangzhou-based company aims to introduce an alternative to popular GLP-1 weight-loss medications, including Wegovy and Zepbound, by using brain-computer interface (BCI) technology to influence hunger signals.
BrainCo founding partner Nyx He described the innovation as an “electronic version of GLP-1”, suggesting that neurostimulation could eventually help regulate appetite without relying on pharmaceutical interventions.
The company expects to commercialise the technology within two to three years, initially targeting China before considering expansion into the United States. Separate medical and consumer versions are reportedly under consideration.
Unlike Neuralink's surgically implanted brain chips, BrainCo primarily develops non-invasive neurotechnology. Its existing portfolio includes intelligent prosthetic hands, neural headsets and robotic technologies supporting healthcare and rehabilitation.
The development signals a potential convergence of artificial intelligence, neuroscience and digital healthcare. If clinically validated, wearable brain stimulation could introduce new approaches to weight management and personalised treatment.
However, significant scientific questions remain unanswered. BrainCo has not publicly released clinical evidence demonstrating the device's effectiveness, making its comparison with established obesity medications an ambitious proposition rather than a proven medical breakthrough.
The larger opportunity lies in transforming healthcare from drug-dependent interventions towards intelligent, technology-assisted therapies. Yet clinical validation, regulatory approval, patient safety and responsible handling of sensitive neural data will determine whether BrainCo's innovation becomes a genuine healthcare breakthrough or remains an experimental concept.
